- Inicio
- Listar por autor
Listar por autor "Ruiz-Irastorza, Guillermo"
Mostrando ítems 1-3 de 3
-
Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough?
Ruiz-Irastorza, Guillermo; Paredes-Ruiz, Diana; Arizpe, Fernando; Campos-Rodriguez, Valerio; Moreno-Torres, Victor; Amo, Laura; Ruiz-Arruza, Ioana; Martin-Iglesias, Daniel (Lupus Science & Medicine, 2025)Objective To assess the daily and weight-adjusted dosages of hydroxychloroquine (HCQ) and the effects on long-term remission in the Lupus-Cruces cohort. Methods Observational study of routine clinical care data. We ... -
Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study
Moreno-Torres, Víctor; Soriano, Vicente; Calderon-Parra, Jorge; Martinez-Urbistondo, Maria; Treviño, Ana; de San Vicente, Zayrho; de Mendoza, Carmen; Ruiz-Irastorza, Guillermo (Autoimmunity Reviews, 2023)INTRODUCTION: SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain. METHODS: Retrospective nation-wide observational ... -
Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies
Moreno-Torres, Víctor; Martín-Iglesias, Daniel; Vivero, Florencia; González-Echavarri, Cristina; García-Moyano, Marta; Enghelmayer, Juan-Ignacio; Malfante, Pablo; Gaser, Adrián; Ruiz-Irastorza, Guillermo (Seminars in Arthritis and Rheumatism, 2023)Objective: To compare the efficacy, toxicity and glucocorticoid (GC)-sparing effects of intravenous cyclophosphamide (iv CYC) with other immunosuppressive regimes as the induction treatment for Idiopathic Inflammatory ...
